Durvalumab supplementation for non-small-cell lung cancer: a meta-analysis study
Durvalumab supplementation may have some potential in improving the efficacy in patients with non-small-cell lung cancer (NSCLC), and this meta-analysis aims to explore the impact of durvalumab supplementation… Read More